• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白甲基转移酶基因 SETD2 是肾透明细胞癌中的一种新的肿瘤抑制基因。

Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.

机构信息

Departments of Genetics and Pathology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.

出版信息

Cancer Res. 2010 Jun 1;70(11):4287-91. doi: 10.1158/0008-5472.CAN-10-0120. Epub 2010 May 25.

DOI:10.1158/0008-5472.CAN-10-0120
PMID:20501857
Abstract

Sporadic clear cell renal cell carcinoma (cRCC) is genetically characterized by the recurrent loss of the short arm of chromosome 3, with a hotspot for copy number loss in the 3p21 region. We applied a method called "gene identification by nonsense-mediated mRNA decay inhibition" to a panel of 10 cRCC cell lines with 3p21 copy number loss to identify biallelic inactivated genes located at 3p21. This revealed inactivation of the histone methyltransferase gene SETD2, located on 3p21.31, as a common event in cRCC cells. SETD2 is nonredundantly responsible for trimethylation of the histone mark H3K36. Consistent with this function, we observed loss or a decrease of H3K36me3 in 7 out of the 10 cRCC cell lines. Identification of missense mutations in 2 out of 10 primary cRCC tumor samples added support to the involvement of loss of SETD2 function in the development of cRCC tumors.

摘要

散发性透明细胞肾细胞癌(cRCC)在遗传学上的特征是 3 号染色体短臂反复缺失,3p21 区域的拷贝数缺失热点。我们应用一种称为“通过无义介导的 mRNA 衰减抑制进行基因鉴定”的方法,对 10 个具有 3p21 拷贝数缺失的 cRCC 细胞系进行分析,以鉴定位于 3p21 上的双等位基因失活基因。这揭示了位于 3p21.31 上的组蛋白甲基转移酶基因 SETD2 的失活是 cRCC 细胞中的常见事件。SETD2 非冗余地负责组蛋白标记 H3K36 的三甲基化。与这一功能一致,我们在 10 个 cRCC 细胞系中的 7 个中观察到 H3K36me3 的缺失或减少。在 10 个原发性 cRCC 肿瘤样本中的 2 个中鉴定出错义突变,进一步支持 SETD2 功能丧失在 cRCC 肿瘤发生中的作用。

相似文献

1
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.组蛋白甲基转移酶基因 SETD2 是肾透明细胞癌中的一种新的肿瘤抑制基因。
Cancer Res. 2010 Jun 1;70(11):4287-91. doi: 10.1158/0008-5472.CAN-10-0120. Epub 2010 May 25.
2
Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.在透明细胞和乳头状肾细胞癌中,RASSF1A 3p21.3肿瘤抑制基因的表观遗传失活。
Cancer Res. 2001 Oct 1;61(19):7277-81.
3
Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).探讨散发性肾透明细胞癌(cRCC)中除 VHL 以外的 3p 缺失肿瘤抑制基因。
Urol Oncol. 2013 Oct;31(7):1333-42. doi: 10.1016/j.urolonc.2011.08.012. Epub 2011 Oct 1.
4
Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.原代肾小管上皮细胞的功能研究表明SETD2在透明细胞肾细胞癌中具有肿瘤抑制作用。
Neoplasia. 2016 Jun;18(6):339-46. doi: 10.1016/j.neo.2016.04.005. Epub 2016 May 26.
5
Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma.微管甲基化单倍不足是肾细胞癌基因组不稳定的早期驱动因素。
Cancer Res. 2018 Jun 15;78(12):3135-3146. doi: 10.1158/0008-5472.CAN-17-3460. Epub 2018 May 3.
6
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.微小RNA-106b-5p靶向肿瘤抑制基因SETD2,使其在肾透明细胞癌中的功能失活。
Oncotarget. 2015 Feb 28;6(6):4066-79. doi: 10.18632/oncotarget.2926.
7
Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.SETD2的缺失而非H3K36me3的缺失与透明细胞肾细胞癌患者的侵袭性临床病理特征相关。
Biosci Trends. 2017 May 23;11(2):214-220. doi: 10.5582/bst.2016.01228. Epub 2017 Mar 6.
8
Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.综合基因组和蛋白质组分析揭示了甲基转移酶 SETD2 在肾细胞癌发展中的新机制。
Mol Cell Proteomics. 2019 Mar;18(3):437-447. doi: 10.1074/mcp.RA118.000957. Epub 2018 Nov 28.
9
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.SETD2 失调的肾细胞癌中 DNA 甲基化的动态重编程
Oncotarget. 2016 Jan 12;7(2):1927-46. doi: 10.18632/oncotarget.6481.
10
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.3p21 组蛋白修饰基因 BAP1 和 SETD2 突变的肾透明细胞癌不良预后:来自 MSKCC 和 KIRC TCGA 研究网络的报告。
Clin Cancer Res. 2013 Jun 15;19(12):3259-67. doi: 10.1158/1078-0432.CCR-12-3886. Epub 2013 Apr 25.

引用本文的文献

1
SETD2 suppresses tumorigenesis in a KRAS-driven lung cancer model, and its catalytic activity is regulated by histone acetylation.SETD2在KRAS驱动的肺癌模型中抑制肿瘤发生,并且其催化活性受组蛋白乙酰化调节。
Elife. 2025 Sep 15;14:RP107451. doi: 10.7554/eLife.107451.
2
SETD2 suppresses tumorigenesis in a KRAS-driven lung cancer model and its catalytic activity is regulated by histone acetylation.SETD2在KRAS驱动的肺癌模型中抑制肿瘤发生,其催化活性受组蛋白乙酰化调节。
bioRxiv. 2025 Jul 14:2025.05.16.654513. doi: 10.1101/2025.05.16.654513.
3
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.
SETD2功能丧失是晚期慢性髓性白血病中的复发性事件,并导致基因组不稳定:慢性髓性白血病中的SETD2缺失。
Clin Transl Med. 2025 Apr;15(4):e70163. doi: 10.1002/ctm2.70163.
4
Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis.整合机器学习揭示色氨酸代谢在肾透明细胞癌中的作用及其与患者预后的关联。
Biol Direct. 2024 Dec 21;19(1):132. doi: 10.1186/s13062-024-00576-w.
5
Construction and validation of a chromatin regulator-related gene signature for prognostic and therapeutic significance of clear cell renal cell carcinoma.用于透明细胞肾细胞癌预后和治疗意义的染色质调节因子相关基因特征的构建与验证
Transl Cancer Res. 2024 Jan 31;13(1):150-172. doi: 10.21037/tcr-23-1383. Epub 2024 Jan 15.
6
A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.肿瘤抑制因子SETD2中的一个错义单核苷酸多态性降低了果蝇中的H3K36me3和有丝分裂纺锤体完整性。
Genetics. 2024 Apr 3;226(4). doi: 10.1093/genetics/iyae015.
7
Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.肿瘤细胞内在的 SETD2 失活通过 NR2F1-STAT1 通路使癌细胞对免疫检查点阻断敏感。
J Immunother Cancer. 2023 Dec 6;11(12):e007678. doi: 10.1136/jitc-2023-007678.
8
Tumor-suppressive functions of protein lysine methyltransferases.蛋白赖氨酸甲基转移酶的肿瘤抑制功能。
Exp Mol Med. 2023 Dec;55(12):2475-2497. doi: 10.1038/s12276-023-01117-7. Epub 2023 Dec 1.
9
The interplay between H3K36 methylation and DNA methylation in cancer.癌症中H3K36甲基化与DNA甲基化之间的相互作用。
Cancer Biol Med. 2023 Aug 18;20(8):545-52. doi: 10.20892/j.issn.2095-3941.2023.0234.
10
Recent advances in developing degraders & inhibitors of lysine methyltransferases.赖氨酸甲基转移酶降解剂和抑制剂的最新研究进展。
Curr Opin Chem Biol. 2023 Oct;76:102356. doi: 10.1016/j.cbpa.2023.102356. Epub 2023 Jun 26.